Novo Nordisk has seen its position in the Chinese diabetes market whittled away in the last couple of years, but it says new products will keep it on top.
Researchers at Texas A&M University have developed a nano-sized delivery system that could help bring injected treatments such as insulin into the oral realm, making the regimen easier on the patient and clinician.
A new study from Washington University has shown that stem cells programmed to act like insulin-secreting beta cells could give Type 1 diabetes patients the treatment they need.
